Pregledni rad

Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ

Mark S. Bartenjev ; Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
Suzana Isaković-Vidović ; General Hospital Jesenice, Jesenice, Slovenia
Igor Bartenjev ; Department of Dermatovenerology, Medical Faculty University of Ljubljana, Ljubljana, Slovenia

Sažetak

Topical imiquimod is a medication approved for the treatment
of external genital and perianal warts, actinic keratosis, and superficial basal
cell carcinoma. There have also been reports of its successful use in patients
with lentigo maligna melanoma in situ. An 80-year-old female patient was
diagnosed with lentigo maligna melanoma in situ which was then surgically
removed. After several recurrences, nonsurgical treatment using topical 5%
imiquimod was introduced. At 9-month follow-up the skin was completely
healed with no evidence of cancer recurrence. In select cases, topical imiquimod
seems to be an effective alternative to surgical treatment of melanoma
in situ (MIS). Further studies are necessary to assess the successfulness of this
treatment method.

Ključne riječi

lentigo melanoma, imiquimod, nonsurgical therapy

Hrčak ID:

246799

URI

https://hrcak.srce.hr/246799

Datum izdavanja:

18.1.2020.

Posjeta: 573 *